• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胃肠道间质瘤的发病率和生存结局。

Incidence and Survival Outcomes of Gastrointestinal Stromal Tumors.

机构信息

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland.

Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.

出版信息

JAMA Netw Open. 2024 Aug 1;7(8):e2428828. doi: 10.1001/jamanetworkopen.2024.28828.

DOI:10.1001/jamanetworkopen.2024.28828
PMID:39158910
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11333982/
Abstract

IMPORTANCE

The incidence of gastrointestinal stromal tumors (GISTs) increased after the implementation of GIST-specific histology coding in 2001, but updated data on trends and survival are lacking.

OBJECTIVE

To examine the evolving epidemiology of GISTs in major organ sites.

DESIGN, SETTING, AND PARTICIPANTS: This descriptive, population-based cohort study used nationally representative data from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program, including the SEER-22 and SEER-17 registries. Data were from evaluated patients aged 20 years or older with GISTs diagnosed between January 1, 2000, and December 31, 2019. Analyses were last updated on October 29, 2023.

MAIN OUTCOMES AND MEASURES

Organ site-specific trends in age-standardized incidence rates and annual percent changes (APCs) in rates were estimated by race and ethnicity and, when possible, by sex, age, and primary indicator. Multivariable Cox proportional hazards regression models were used to examine racial and ethnic differences in overall and GIST-specific survival by site.

RESULTS

The SEER-22 and SEER-17 datasets contained 23 001 and 12 109 case patients with GISTs, respectively. Patients in the SEER-22 registry had a mean (SD) age of 64 (13) years and 51.3% were men. With regard to race and ethnicity, 9.7% of patients were Asian or Pacific Islander, 12.3% were Hispanic, 19.6% were non-Hispanic Black, and 57.7% were non-Hispanic White. Overall incidence rates of GISTs in the SEER-22 cohort increased substantially over time for all organ sites but the colon (APCs: esophagus, 7.3% [95% CI, 4.4% to 10.2%]; gastric, 5.1% [95% CI, 4.2% to 6.1%]; small intestine, 2.7% [95% CI, 1.8% to 3.7%]; colon, -0.2% [95% CI, -1.3% to 0.9%]; and rectum, 1.9% [95% CI, 0.1% to 3.8%]). There were similar increasing trends by age groups (<50 vs ≥50 years), sex, race and ethnicity, and primary indicator for gastric and small intestine GISTs. Increases were mainly restricted to localized stage disease. Patients in the SEER-17 cohort had a mean (SD) age of 64 (14) years and 51.9% were men. With regard to race and ethnicity, 13.3% of patients were Asian or Pacific Islander, 11.6% were Hispanic, 17.8% were non-Hispanic Black, and 56.6% were non-Hispanic White. Non-Hispanic Black individuals had higher overall mortality for esophageal (adjusted hazard ratio [HR], 6.4 [95% CI, 2.0 to 20.3]) and gastric (adjusted HR, 1.4 [95% CI, 1.2 to 1.5]) GISTs compared with non-Hispanic White individuals. Asian or Pacific Islander individuals also had higher overall mortality for esophageal GISTs (adjusted HR, 5.6 [95% CI, 1.5 to 20.2]). Results were similar for GIST-specific survival.

CONCLUSIONS AND RELEVANCE

In this cohort study using SEER data, the incidence of GISTs in major organ sites increased in the last 2 decades among several population groups. These findings suggest that additional studies are warranted to identify risk factors, because histologic reclassification and higher availability of endoscopy and imaging do not fully explain these unfavorable incidence trends. Prevention efforts are needed to reduce the substantial survival disparities among racial and ethnic minoritized populations.

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71e1/11333982/13031ec9efbe/jamanetwopen-e2428828-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71e1/11333982/52b03109e99c/jamanetwopen-e2428828-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71e1/11333982/4b8687ed18be/jamanetwopen-e2428828-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71e1/11333982/13031ec9efbe/jamanetwopen-e2428828-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71e1/11333982/52b03109e99c/jamanetwopen-e2428828-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71e1/11333982/4b8687ed18be/jamanetwopen-e2428828-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71e1/11333982/13031ec9efbe/jamanetwopen-e2428828-g003.jpg
摘要

重要性

2001 年实施 GIST 特异性组织学编码后,胃肠道间质瘤 (GIST) 的发病率增加,但缺乏关于趋势和生存的最新数据。

目的

研究主要器官部位 GIST 的不断演变的流行病学。

设计、地点和参与者:本描述性、基于人群的队列研究使用了美国国立癌症研究所监测、流行病学和最终结果 (SEER) 计划的全国代表性数据,包括 SEER-22 和 SEER-17 登记处。数据来自 2000 年 1 月 1 日至 2019 年 12 月 31 日期间诊断为 GIST 的年龄在 20 岁或以上的评估患者。分析最后一次更新于 2023 年 10 月 29 日。

主要结果和措施

通过种族和民族以及可能的性别、年龄和主要指标,估计了各器官部位年龄标准化发病率和发病率年变化率 (APC) 的趋势。使用多变量 Cox 比例风险回归模型检查了不同种族和民族在特定部位和总体生存方面的差异。

结果

SEER-22 和 SEER-17 数据集分别包含 23001 例和 12109 例 GIST 患者。SEER-22 登记处的患者平均(SD)年龄为 64(13)岁,51.3%为男性。关于种族和民族,9.7%的患者为亚洲或太平洋岛民,12.3%为西班牙裔,19.6%为非西班牙裔黑人,57.7%为非西班牙裔白人。SEER-22 队列中所有器官部位的 GIST 总体发病率随着时间的推移大幅增加,但结肠除外(APC:食管,7.3%[95%CI,4.4%至 10.2%];胃,5.1%[95%CI,4.2%至 6.1%];小肠,2.7%[95%CI,1.8%至 3.7%];结肠,-0.2%[95%CI,-1.3%至 0.9%];直肠,1.9%[95%CI,0.1%至 3.8%])。各年龄组(<50 岁与≥50 岁)、性别、种族和民族以及胃和小肠 GIST 的主要指标也存在类似的上升趋势。增加主要限于局部阶段疾病。SEER-17 队列的患者平均(SD)年龄为 64(14)岁,51.9%为男性。关于种族和民族,13.3%的患者为亚洲或太平洋岛民,11.6%为西班牙裔,17.8%为非西班牙裔黑人,56.6%为非西班牙裔白人。与非西班牙裔白人相比,非西班牙裔黑人的食管(调整后的危险比[HR],6.4[95%CI,2.0 至 20.3])和胃(调整后的 HR,1.4[95%CI,1.2 至 1.5])GIST 的总死亡率更高。亚洲或太平洋岛民的食管 GIST 总死亡率也更高(调整后的 HR,5.6[95%CI,1.5 至 20.2])。GIST 特异性生存的结果相似。

结论和相关性

在这项使用 SEER 数据的队列研究中,在过去 20 年中,几个人群的主要器官部位的 GIST 发病率增加。这些发现表明,需要进一步研究以确定风险因素,因为组织学重新分类以及内窥镜和影像学的更高可用性并不能完全解释这些不利的发病趋势。需要采取预防措施来减少少数族裔人群在生存方面的巨大差异。

相似文献

1
Incidence and Survival Outcomes of Gastrointestinal Stromal Tumors.胃肠道间质瘤的发病率和生存结局。
JAMA Netw Open. 2024 Aug 1;7(8):e2428828. doi: 10.1001/jamanetworkopen.2024.28828.
2
Variation in Breast Cancer Subtype Incidence and Distribution by Race/Ethnicity in the United States From 2010 to 2015.2010 年至 2015 年美国不同种族/族裔乳腺癌亚型发病率和分布的变化。
JAMA Netw Open. 2020 Oct 1;3(10):e2020303. doi: 10.1001/jamanetworkopen.2020.20303.
3
Racial Disparity in Incidence and Survival for Gastrointestinal Stromal Tumors (GISTs): an Analysis of SEER Database.种族差异对胃肠道间质瘤(GISTs)的发病率和生存率的影响:SEER 数据库分析。
J Racial Ethn Health Disparities. 2019 Oct;6(5):1035-1043. doi: 10.1007/s40615-019-00605-9. Epub 2019 Jun 18.
4
Population-Based Epidemiology and Mortality of Small Malignant Gastrointestinal Stromal Tumors in the USA.美国小型恶性胃肠道间质瘤的基于人群的流行病学和死亡率
J Gastrointest Surg. 2016 Jun;20(6):1132-40. doi: 10.1007/s11605-016-3134-y. Epub 2016 Mar 29.
5
Incidence Rate Trends of Breast Cancer Overall and by Molecular Subtype by Race and Ethnicity and Age.按种族、民族和年龄划分的乳腺癌总体及分子亚型的发病率趋势。
JAMA Netw Open. 2025 Jan 2;8(1):e2456142. doi: 10.1001/jamanetworkopen.2024.56142.
6
State Variation in Racial and Ethnic Disparities in Incidence of Triple-Negative Breast Cancer Among US Women.美国女性中三阴性乳腺癌发病率的种族和民族差异的州际变化。
JAMA Oncol. 2023 May 1;9(5):700-704. doi: 10.1001/jamaoncol.2022.7835.
7
Changing Disparity of Gastric Cancer Incidence by Histological Types in US Race-Specific Populations.美国特定种族人群中组织学类型胃癌发病率的差异变化。
Cancer Control. 2020 Jan-Dec;27(1):1073274820977152. doi: 10.1177/1073274820977152.
8
Differential Outcomes Among Survivors of Head and Neck Cancer Belonging to Racial and Ethnic Minority Groups.头颈部癌症幸存者的不同结局属于少数族裔群体。
JAMA Otolaryngol Head Neck Surg. 2022 Feb 1;148(2):119-127. doi: 10.1001/jamaoto.2021.3425.
9
Racial Disparities and Trends in Outcomes of Patients with Gastrointestinal Stromal Tumors.胃肠道间质瘤患者的种族差异及预后趋势
J Gastrointest Cancer. 2025 Feb 28;56(1):72. doi: 10.1007/s12029-025-01195-y.
10
Uterine cancer incidence trends and 5-year relative survival by race/ethnicity and histology among women under 50 years.50 岁以下女性中按种族/族裔和组织学划分的子宫癌发病率趋势和 5 年相对生存率
Am J Obstet Gynecol. 2024 Nov;231(5):526.e1-526.e22. doi: 10.1016/j.ajog.2024.06.026. Epub 2024 Jun 24.

引用本文的文献

1
Trends and outcomes for patients receiving neoadjuvant therapy for stage I to III gastric gastrointestinal stromal tumors.接受新辅助治疗的Ⅰ至Ⅲ期胃胃肠道间质瘤患者的趋势与预后
J Gastrointest Surg. 2025 Aug;29(8):102117. doi: 10.1016/j.gassur.2025.102117. Epub 2025 Jun 16.
2
Minimally invasive approaches to small gastric stromal tumors: The less with the more.小胃间质瘤的微创治疗方法:越少越好。
World J Gastrointest Surg. 2025 May 27;17(5):101823. doi: 10.4240/wjgs.v17.i5.101823.
3
Expanding the role of endoscopic resection in esophageal gastrointestinal stromal tumors: Insights and challenges.

本文引用的文献

1
NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022.NCCN 指南洞察版:胃肠道间质瘤,2022 年第 2 版。
J Natl Compr Canc Netw. 2022 Nov;20(11):1204-1214. doi: 10.6004/jnccn.2022.0058.
2
Disparities in Access to Endoscopy for Patients With Upper Gastrointestinal Bleeding Presenting to Emergency Departments.就诊于急诊科的上消化道出血患者在内镜检查可及性方面的差异
Gastroenterology. 2023 Jun;164(7):1044-1046.e4. doi: 10.1053/j.gastro.2022.10.001. Epub 2022 Oct 10.
3
Gastrointestinal Stromal Tumors (GIST): A Population-Based Study Using the SEER Database, including Management and Recent Advances in Targeted Therapy.
扩大内镜切除术在食管胃肠道间质瘤中的作用:见解与挑战。
World J Gastroenterol. 2025 May 28;31(20):106441. doi: 10.3748/wjg.v31.i20.106441.
4
Long-term outcomes of endoscopic treatment versus surgical resection for 0-2 cm gastrointestinal stromal tumor: A SEER database study.内镜治疗与手术切除治疗0-2厘米胃肠道间质瘤的长期结局:一项监测、流行病学和最终结果(SEER)数据库研究
Surg Endosc. 2025 May 14. doi: 10.1007/s00464-025-11720-6.
5
The Prediagnostic General Practitioners' Pathway of Gastrointestinal Stromal Tumor Patients: A Real-World Data Study.胃肠道间质瘤患者的诊断前全科医生诊疗路径:一项真实世界数据研究。
Cancers (Basel). 2025 Apr 22;17(9):1391. doi: 10.3390/cancers17091391.
6
Annual Report to the Nation on the Status of Cancer, featuring state-level statistics after the onset of the COVID-19 pandemic.《美国癌症现状年度报告》,重点介绍了新冠疫情爆发后的州级统计数据。
Cancer. 2025 May 1;131(9):e35833. doi: 10.1002/cncr.35833.
7
Establishment and validation of a prognostic nomogram for extra-gastrointestinal stromal tumors.胃肠道外间质瘤预后列线图的建立与验证
Front Oncol. 2025 Mar 20;15:1527237. doi: 10.3389/fonc.2025.1527237. eCollection 2025.
8
Significance of monitoring imatinib plasma concentration in second-line treatment decisions for gene-mutated gastrointestinal stromal tumors.监测伊马替尼血药浓度在基因变异型胃肠道间质瘤二线治疗决策中的意义
World J Gastrointest Oncol. 2025 Mar 15;17(3):98746. doi: 10.4251/wjgo.v17.i3.98746.
9
Trends and Financial Burden of Gastrointestinal Stromal Tumors in the United States: A Comprehensive Analysis of United States Hospitalizations.美国胃肠道间质瘤的趋势与经济负担:对美国住院情况的综合分析
Gastroenterology Res. 2025 Feb;18(1):12-22. doi: 10.14740/gr2009. Epub 2025 Feb 6.
10
Racial Disparities and Trends in Outcomes of Patients with Gastrointestinal Stromal Tumors.胃肠道间质瘤患者的种族差异及预后趋势
J Gastrointest Cancer. 2025 Feb 28;56(1):72. doi: 10.1007/s12029-025-01195-y.
胃肠道间质瘤(GIST):一项基于监测、流行病学和最终结果(SEER)数据库的人群研究,包括管理及靶向治疗的最新进展
Cancers (Basel). 2022 Jul 28;14(15):3689. doi: 10.3390/cancers14153689.
4
The Incidence of Gastrointestinal Stromal Tumors in Obese Patients-A Large Single Center Experience.肥胖患者胃肠道间质瘤的发病率——一项大型单中心经验
Medicina (Kaunas). 2021 Nov 14;57(11):1242. doi: 10.3390/medicina57111242.
5
Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.胃肠道间质瘤:ESMO-EURACAN-GENTURIS诊断、治疗及随访临床实践指南
Ann Oncol. 2022 Jan;33(1):20-33. doi: 10.1016/j.annonc.2021.09.005. Epub 2021 Sep 21.
6
Carney Triad, Carney-Stratakis Syndrome, 3PAS and Other Tumors Due to SDH Deficiency.卡尼三联征、卡尼-斯特拉塔斯基综合征、3PAS 和其他因 SDH 缺陷引起的肿瘤。
Front Endocrinol (Lausanne). 2021 May 3;12:680609. doi: 10.3389/fendo.2021.680609. eCollection 2021.
7
Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial.阿伐普替尼治疗不可切除或转移性 PDGFRA D842V 突变胃肠间质瘤:NAVIGATOR Ⅰ期试验的长期疗效和安全性数据。
Eur J Cancer. 2021 Mar;145:132-142. doi: 10.1016/j.ejca.2020.12.008. Epub 2021 Jan 16.
8
The management of metastatic GIST: current standard and investigational therapeutics.转移性 GIST 的治疗管理:当前标准和研究治疗方法。
J Hematol Oncol. 2021 Jan 5;14(1):2. doi: 10.1186/s13045-020-01026-6.
9
Incidence and time trends of sarcoma (2000-2013): results from the French network of cancer registries (FRANCIM).肉瘤的发病率和时间趋势(2000-2013):来自法国癌症登记处网络(FRANCIM)的结果。
BMC Cancer. 2020 Mar 6;20(1):190. doi: 10.1186/s12885-020-6683-0.
10
Association of Race and Socioeconomic Status With Colorectal Cancer Screening, Colorectal Cancer Risk, and Mortality in Southern US Adults.种族和社会经济地位与美国南部成年人结直肠癌筛查、结直肠癌风险和死亡率的关联。
JAMA Netw Open. 2019 Dec 2;2(12):e1917995. doi: 10.1001/jamanetworkopen.2019.17995.